Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG).
暂无分享，去创建一个
A. Hein | R. Glasspool | F. Marmé | T. Petit | J. Rau | F. Joly | P. Harter | S. Mahner | B. Schmalfeldt | J. Pfisterer | A. El-Balat | L. Hanker | N. de Gregorio | A. Dean | J. Kurtz | K. Baumann | U. Canzler | C. Shannon | D. Reimer | J. Sehouli